The available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction are discussed by guests Chris Memering, MSN, RN, CDCES, BC-ADM, FADCES, and Sun Kim, MD. A particular emphasis on GLP-1 receptor agonists and the patients for whom they are guideline-recommended, as well as ongoing research, are also covered.
Earn 0.6 CE contact hours, including 0.6 pharmacology, from listening by listening to the podcast episode and completing the course components.
Learning Objectives
- Discuss available novel diabetes therapies and their impact on cardiovascular and cardiometabolic risk reduction
- Explore the mechanism of action and study results of the GLP1 medication class
CE certificate available upon successful completion of the post-test and program evaluation.
MD
MSN, RN, CDCES, BC-ADM, FADCES
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
